ADAR1 Capital Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), ADAR1 Capital Management, LLC reported 231 stock positions worth $496.6 million. Its top holding was Protagonist Therapeutics (PTGX) at 11.2% of the portfolio, followed by Cytokinetics (CYTK, 9.3%) and Roivant Sciences (ROIV, 8.8%). Compared with Q1 2024, it opened 61 new positions, sold out of 53, added to 88 and reduced 43. The biggest buy was Protagonist Therapeutics (PTGX, shares +104%) and the biggest sale Alnylam Pharmaceuticals (ALNY, shares −99%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $496.6M (Q2 2024)
- SEC Filing
- 0001940267-24-000001 ↗ filed Aug 13, 2024
Holdings Value
Holdings 231 stocks · $496.6M
| PTGX Protagonist Therapeutics Inc. | 11.19% | 1,603,932 | $55.6M | Add +104.2% |
| CYTK Cytokinetics Inc. | 9.32% | 853,862 | $46.3M | Add +167.2% |
| ROIV Roivant Sciences Ltd. | 8.83% | 4,150,009 | $43.9M | Add +48.6% |
| BOXX Alpha Architect 1-3 MNTH Box | 7.63% | 351,482 | $37.9M | Add +10.5% |
| BBIO Bridgebio Pharma Inc. | 6.45% | 1,264,570 | $32.0M | Add +130.0% |
| RPRX Royalty Pharma PLC Class A | 6.27% | 1,181,332 | $31.2M | Add +63.8% |
| KROS Keros Therapeutics Inc. | 5.05% | 548,916 | $25.1M | Add +62.3% |
| IMVT Immunovant Inc. | 2.53% | 476,543 | $12.6M | Add +684.3% |
| ABUS Arbutus Biopharma Corp. | 2.05% | 3,289,260 | $10.2M | Add +58.6% |
| MRK Merck & Co. Inc. | 1.89% | 75,750 | $9.4M | Add +25150.0% |
| RZLT Rezolute Inc. | 1.79% | 2,063,962 | $8.9M | New |
| SLDB Solid Biosciences Inc. | 1.62% | 1,420,422 | $8.1M | Add +599.0% |
| EWTX Edgewise Therapeutics Inc. | 1.58% | 436,608 | $7.9M | Add +141.3% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 1.52% | 750,000 | $7.5M | New |
| ASND Ascendis Pharma A/S | 1.41% | 51,263 | $7.0M | Add +5.5% |
| TECX Tectonic Therapeutic Inc. | 1.18% | 356,878 | $5.9M | New |
| QURE Uniqure NV | 1.10% | 1,222,676 | $5.5M | Add +317.5% |
| ABSI Absci Corp. | 1.05% | 1,698,529 | $5.2M | Add +189.4% |
| VKTX Viking Therapeutics Inc. | 0.97% | 91,227 | $4.8M | Add +533.5% |
| ALKS Alkermes PLC | 0.95% | 196,577 | $4.7M | Add +25.5% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.83% | 404,138 | $4.1M | Add +0.2% |
| ANAB Anaptysbio Inc. | 0.79% | 155,799 | $3.9M | Add +15479.9% |
| CERE Cerevel Therapeutics Holding | 0.77% | 93,350 | $3.8M | Add +284.8% |
| CRNX Crinetics Pharmaceuticals Inc. | 0.68% | 74,850 | $3.4M | New |
| BIL SS SPDR BB 1-3M T-Bill ETF | 0.60% | 32,500 | $3.0M | No change |
| INSM Insmed Inc. | 0.57% | 42,217 | $2.8M | New |
| QTTB Q32 Bio Inc. | 0.57% | 156,504 | $2.8M | Reduce -16.6% |
| ACASTI PHARMA INC | 0.56% | 959,571 | $2.8M | Add +341.4% |
| VUSB Vanguard Ultra Short Bond Et | 0.55% | 55,206 | $2.7M | No change |
| JPST JPMorgan Ultra-Short Income | 0.55% | 54,000 | $2.7M | No change |
| SHV iShares 0-1 Year Treasury Bo | 0.55% | 24,500 | $2.7M | No change |
| SVRA Savara Inc. | 0.54% | 663,598 | $2.7M | Add +11750.0% |
| OABI Omniab Inc. | 0.54% | 712,560 | $2.7M | Add +57.8% |
| USFR Wisdomtree Floating Rate Tre | 0.54% | 53,000 | $2.7M | No change |
| ACHV Achieve Life Sciences Inc. | 0.51% | 542,233 | $2.5M | Reduce -38.0% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.46% | 253,197 | $2.3M | Add +22.4% |
| FULC Fulcrum Therapeutics Inc. | 0.46% | 368,369 | $2.3M | Add +8.4% |
| KALA Kala Bio Inc. | 0.44% | 306,067 | $2.2M | New |
| KNSA Kiniksa Pharmaceuticals Inte | 0.43% | 114,309 | $2.1M | Add +91.5% |
| ULST SS Ultra Short TM Bond ETF | 0.39% | 47,684 | $1.9M | No change |
| BEAM Beam Therapeutics Inc. | 0.34% | 72,800 | $1.7M | New |
| CLRB Cellectar Biosciences Inc. | 0.34% | 682,094 | $1.7M | Add +6.2% |
| TEVA Teva Pharmaceutical-SP ADR | 0.34% | 103,121 | $1.7M | Add +1.5% |
| DCTH Delcath Systems Inc. | 0.33% | 198,347 | $1.7M | Reduce -9.4% |
| SLNO Soleno Therapeutics Inc. | 0.33% | 39,929 | $1.6M | New |
| APGE Apogee Therapeutics Inc. | 0.32% | 40,875 | $1.6M | Add +581.3% |
| MRUS Merus NV | 0.32% | 26,850 | $1.6M | New |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 0.32% | 11,100 | $1.6M | Reduce -64.8% |
| AURA Aura Biosciences Inc. | 0.31% | 203,237 | $1.5M | New |
| KYMR Kymera Therapeutics Inc. | 0.30% | 50,626 | $1.5M | Add +216.4% |
| APLT Applied Therapeutics Inc. | 0.30% | 320,727 | $1.5M | Reduce -29.8% |
| CNTX Context Therapeutics Inc. | 0.26% | 645,161 | $1.3M | Add +213.3% |
| ATXS Astria Therapeutics Inc. | 0.25% | 138,158 | $1.3M | Add +2869.9% |
| IBIO Ibio Inc. | 0.24% | 570,000 | $1.2M | Reduce -5.0% |
| SPRO Spero Therapeutics Inc. | 0.24% | 918,929 | $1.2M | Reduce -0.9% |
| INDV Indivior Ltd. | 0.23% | 70,007 | $1.1M | Add +153.6% |
| PFE Pfizer Inc. | 0.23% | 39,950 | $1.1M | Reduce -62.4% |
| NVNO Envveno Medical Corporation | 0.21% | 201,728 | $1.1M | No change |
| TH Target Hospitality Corp. | 0.20% | 113,626 | $990K | New |
| GH Guardant Health Inc. | 0.20% | 34,000 | $982K | Add +100.0% |
| VIR Vir Biotechnology Inc. | 0.20% | 110,000 | $979K | New |
| CGEM Cullinan Therapeutics Inc. | 0.19% | 53,261 | $929K | New |
| PCVX Vaxcyte Inc. | 0.19% | 12,250 | $925K | Add +512.5% |
| ITOS Iteos Therapeutics Inc. | 0.18% | 60,000 | $890K | New |
| ALEC Alector Inc. | 0.18% | 195,311 | $887K | Add +272.0% |
| DNLI Denali Therapeutics Inc. | 0.18% | 38,000 | $882K | Add +1800.0% |
| ANGO Angiodynamics Inc. | 0.18% | 143,862 | $870K | Reduce -6.2% |
| ARVN Arvinas Inc. | 0.17% | 32,400 | $862K | Add +23.7% |
| SYRE Spyre Therapeutics Inc. | 0.17% | 35,180 | $827K | Reduce -28.9% |
| AGR Avangrid Inc. | 0.16% | 23,000 | $817K | New |
| KVAUF Keen Vision Acquisition Corp. | 0.16% | 75,000 | $793K | No change |
| APLS Apellis Pharmaceuticals Inc. | 0.16% | 20,650 | $792K | Reduce -19.6% |
| SLN Silence Therapeutics PLC-ADR | 0.15% | 40,290 | $766K | Add +0.5% |
| KPRX Kiora Pharmaceuticals Inc. | 0.15% | 172,596 | $725K | Add +36.1% |
| SRPT Sarepta Therapeutics Inc. | 0.14% | 4,450 | $703K | Reduce -85.7% |
| CTMX Cytomx Therapeutics Inc. | 0.14% | 572,170 | $698K | Add +269.1% |
| CATX Perspective Therapeutics Inc. | 0.14% | 69,985 | $698K | New |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.14% | 97,695 | $695K | New |
| XAIR Beyond Air Inc. | 0.13% | 1,225,270 | $658K | Add +1.7% |
| KEZAR LIFE SCIENCES INC | 0.13% | 1,086,498 | $652K | Add +359.2% |
| VXRT Vaxart Inc. | 0.13% | 945,568 | $631K | New |
| CTVA Corteva Inc. | 0.12% | 11,400 | $615K | Reduce -69.5% |
| ARYD Arya Sciences Acquisition-A | 0.12% | 53,527 | $614K | Add +30.8% |
| AKRO Akero Therapeutics Inc. | 0.12% | 25,507 | $598K | Add +1311.6% |
| TSHA Taysha Gene Therapies Inc. | 0.11% | 250,800 | $562K | Add +476.6% |
| ATNM Actinium Pharmaceuticals Inc. | 0.11% | 75,133 | $556K | Reduce -24.9% |
| TMTC TMT Acquisition Corp. Class A | 0.11% | 50,000 | $549K | No change |
| CRBP Corbus Pharmaceuticals Holdi | 0.11% | 12,000 | $543K | Reduce -25.0% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.11% | 13,000 | $534K | Add +4.8% |
| ARDX Ardelyx Inc. | 0.10% | 70,000 | $519K | New |
| YEAR AB Ultra Short Income ETF filed as AB ACTIVE ETFS INC | 0.10% | 10,000 | $505K | No change |
| PULS Pgim Ultra Short Bond ETF | 0.10% | 10,000 | $497K | No change |
| STVN Stevanato Group SPA | 0.10% | 27,000 | $495K | Add +74.2% |
| DAWN Day One Biopharmaceuticals I | 0.10% | 35,100 | $484K | New |
| GOSS Gossamer Bio Inc. | 0.10% | 532,628 | $480K | Reduce -27.3% |
| ABEO Abeona Therapeutics Inc. | 0.10% | 113,125 | $480K | New |
| ALNY Alnylam Pharmaceuticals Inc. | 0.09% | 1,850 | $450K | Reduce -99.0% |
| PYPD Polypid Ltd. | 0.09% | 103,950 | $447K | New |
| SNY Sanofi-ADR | 0.09% | 9,100 | $442K | Add +65.5% |
| TXMD Therapeuticsmd Inc. | 0.09% | 270,160 | $435K | Reduce -0.7% |
Options reported separately and not counted above: INSM puts ($13.5M), INSM calls ($10.1M), SPY puts ($4.4M), CERE puts ($2.1M), QQQ puts ($1.4M), IWM puts ($609K), MRNA calls ($594K), FULC calls ($124K), CAPR puts ($97K), BBIO calls ($94K), SVRA puts ($44K), GLYCOMIMETICS INC puts ($38K), and 9 more.
Other holdings (14): bonds, preferreds, convertibles and warrants · $51K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| TMTCR TMT Acquisition Corp.-RT | RIGHT 03/27/2028 | 49,900 | $17K | No change |
| GLSTR Global Star Acquisition-RTS | RIGHT 99/99/9999 | 118,400 | $15K | No change |
| OAKUR Oak Woods Acquisition Cor-RT | RIGHT 03/23/2028 | 30,000 | $8K | No change |
| GLSTW Global Star Acquisition-27 A | *W EXP 07/15/202 | 120,000 | $3K | No change |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | 18,000 | $2K | No change |
| CETUR Cetus Capital Acquisition Co. | RIGHT 03/31/2024 | 4,999 | $1K | No change |
| SBCWW Pono Capital Two Inc. -27 | *W EXP 09/17/202 | 19,800 | $1K | No change |
| OAKUW Oak Woods Acquisition -28 | *W EXP 99/99/999 | 30,000 | $750 | No change |
| ECD AUTOMOTIVE DESIGN INC | *W EXP 12/12/202 | 32,596 | $652 | No change |
| FTIIW Futuretech II Acq -CW27 | *W EXP 08/18/202 | 30,000 | $483 | No change |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | 18,000 | $378 | No change |
| AIMWF Aimfinity Investment-CW27 | *W EXP 99/99/999 | 18,000 | $362 | No change |
| FORLW Four Leaf Acquisition Cor-28 | *W EXP 03/15/202 | 7,987 | $360 | Reduce -15.8% |
| CETUW Cetus Capital Acquisition-28 | *W EXP 01/31/202 | 5,000 | $130 | No change |
Total filed on the 13F, all lines: $496.6M.
Portfolio Sells Q1 2024 → Q2 2024
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -99.0% | 0.09% | −7.26 |
| MACK Merrimack Pharmaceuticals Inc. | Sold out | 0.00% | −3.64 |
| AVROBIO INC | Sold out | 0.00% | −1.38 |
| EDR Endeavor Group Hold Class A | Reduce -93.2% | 0.06% | −1.03 |
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −1.03 |
| ONC Beone Medicines Ltd.-ADR | Reduce -64.8% | 0.32% | −1.03 |
| SRPT Sarepta Therapeutics Inc. | Reduce -85.7% | 0.14% | −0.96 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −0.60 |
| PFE Pfizer Inc. | Reduce -62.4% | 0.23% | −0.58 |
| ACHV Achieve Life Sciences Inc. | Reduce -38.0% | 0.51% | −0.57 |
| APLT Applied Therapeutics Inc. | Reduce -29.8% | 0.30% | −0.55 |
| LGND Ligand Pharmaceuticals | Reduce -96.7% | 0.02% | −0.52 |
| SDGR Schrodinger Inc. | Sold out | 0.00% | −0.47 |
| CTVA Corteva Inc. | Reduce -69.5% | 0.12% | −0.47 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −0.40 |
| IBIO Ibio Inc. | Reduce -5.0% | 0.24% | −0.36 |
| NGM NGM Biopharmaceuticals Inc. | Sold out | 0.00% | −0.35 |
| SYRE Spyre Therapeutics Inc. | Reduce -28.9% | 0.17% | −0.35 |
| QTTB Q32 Bio Inc. | Reduce -16.6% | 0.57% | −0.31 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -19.6% | 0.16% | −0.25 |
| GLST Global Star Acquisition Class A | Sold out | 0.00% | −0.23 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.22 |
| VYGR Voyager Therapeutics Inc. | Reduce -79.6% | 0.03% | −0.20 |
| SPRO Spero Therapeutics Inc. | Reduce -0.9% | 0.24% | −0.19 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −0.19 |
| GOSS Gossamer Bio Inc. | Reduce -27.3% | 0.10% | −0.14 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| NRIX Nurix Therapeutics Inc. | Reduce -90.2% | 0.01% | −0.13 |
| TYRA Tyra Biosciences Inc. | Reduce -98.9% | 0.00% | −0.13 |
| EQ Equillium Inc. | Reduce -29.2% | 0.02% | −0.11 |
| WST West Pharmaceutical Services | Reduce -40.7% | 0.06% | −0.10 |
| ATNM Actinium Pharmaceuticals Inc. | Reduce -24.9% | 0.11% | −0.10 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −0.10 |
| SCRM Screaming Eagle Acq Class A | Sold out | 0.00% | −0.09 |
| TXMD Therapeuticsmd Inc. | Reduce -0.7% | 0.09% | −0.08 |
| GOOGL Alphabet Inc. Class A | Sold out | 0.00% | −0.08 |
| JANX Janux Therapeutics Inc. | Reduce -43.6% | 0.07% | −0.08 |
| ANGO Angiodynamics Inc. | Reduce -6.2% | 0.18% | −0.07 |
| VERU Veru Inc. | Sold out | 0.00% | −0.06 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -25.0% | 0.11% | −0.06 |
| IMTX Immatics NV | Sold out | 0.00% | −0.05 |
| AQN Algonquin Power & Utilities | Reduce -59.5% | 0.02% | −0.05 |
| AIEV Thunder Power Holdings Inc. | Reduce -90.0% | 0.00% | −0.04 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.04 |
| SPRB Spruce Biosciences Inc. | Reduce -2.7% | 0.04% | −0.04 |
| MCK McKesson Corp. | Sold out | 0.00% | −0.04 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| GHRS GH Research PLC | Reduce -85.3% | 0.00% | −0.03 |
| JD Jd.com Inc.-ADR | Sold out | 0.00% | −0.03 |
| FORL Four Leaf Acquisition Cor-A | Sold out | 0.00% | −0.03 |
Portfolio Buys Q1 2024 → Q2 2024
| PTGX Protagonist Therapeutics Inc. | Add +104.2% | 11.19% | +4.99 |
| CYTK Cytokinetics Inc. | Add +167.2% | 9.32% | +3.20 |
| IMVT Immunovant Inc. | Add +684.3% | 2.53% | +2.00 |
| MRK Merck & Co. Inc. | Add +25150.0% | 1.89% | +1.88 |
| BBIO Bridgebio Pharma Inc. | Add +130.0% | 6.45% | +1.81 |
| RZLT Rezolute Inc. | New | 1.79% | +1.79 |
| FRNM Freenome Inc. | New | 1.52% | +1.52 |
| TECX Tectonic Therapeutic Inc. | New | 1.18% | +1.18 |
| SLDB Solid Biosciences Inc. | Add +599.0% | 1.62% | +0.88 |
| ROIV Roivant Sciences Ltd. | Add +48.6% | 8.83% | +0.80 |
| ANAB Anaptysbio Inc. | Add +15479.9% | 0.79% | +0.78 |
| QURE Uniqure NV | Add +317.5% | 1.10% | +0.69 |
| EWTX Edgewise Therapeutics Inc. | Add +141.3% | 1.58% | +0.68 |
| CRNX Crinetics Pharmaceuticals Inc. | New | 0.68% | +0.68 |
| VKTX Viking Therapeutics Inc. | Add +533.5% | 0.97% | +0.65 |
| ABUS Arbutus Biopharma Corp. | Add +58.6% | 2.05% | +0.59 |
| INSM Insmed Inc. | New | 0.57% | +0.57 |
| SVRA Savara Inc. | Add +11750.0% | 0.54% | +0.53 |
| CERE Cerevel Therapeutics Holding | Add +284.8% | 0.77% | +0.49 |
| KALA Kala Bio Inc. | New | 0.44% | +0.44 |
| ACASTI PHARMA INC | Add +341.4% | 0.56% | +0.36 |
| BEAM Beam Therapeutics Inc. | New | 0.34% | +0.34 |
| SLNO Soleno Therapeutics Inc. | New | 0.33% | +0.33 |
| MRUS Merus NV | New | 0.32% | +0.32 |
| AURA Aura Biosciences Inc. | New | 0.31% | +0.31 |
| RPRX Royalty Pharma PLC Class A | Add +63.8% | 6.27% | +0.29 |
| ATXS Astria Therapeutics Inc. | Add +2869.9% | 0.25% | +0.24 |
| APGE Apogee Therapeutics Inc. | Add +581.3% | 0.32% | +0.22 |
| TH Target Hospitality Corp. | New | 0.20% | +0.20 |
| VIR Vir Biotechnology Inc. | New | 0.20% | +0.20 |
| CGEM Cullinan Therapeutics Inc. | New | 0.19% | +0.19 |
| CNTX Context Therapeutics Inc. | Add +213.3% | 0.26% | +0.18 |
| ITOS Iteos Therapeutics Inc. | New | 0.18% | +0.18 |
| DNLI Denali Therapeutics Inc. | Add +1800.0% | 0.18% | +0.17 |
| AGR Avangrid Inc. | New | 0.16% | +0.16 |
| PCVX Vaxcyte Inc. | Add +512.5% | 0.19% | +0.15 |
| ABSI Absci Corp. | Add +189.4% | 1.05% | +0.14 |
| CATX Perspective Therapeutics Inc. | New | 0.14% | +0.14 |
| CLYM Climb Bio Inc. | New | 0.14% | +0.14 |
| KYMR Kymera Therapeutics Inc. | Add +216.4% | 0.30% | +0.13 |
| VXRT Vaxart Inc. | New | 0.13% | +0.13 |
| KNSA Kiniksa Pharmaceuticals Inte | Add +91.5% | 0.43% | +0.11 |
| AKRO Akero Therapeutics Inc. | Add +1311.6% | 0.12% | +0.11 |
| ARDX Ardelyx Inc. | New | 0.10% | +0.10 |
| GH Guardant Health Inc. | Add +100.0% | 0.20% | +0.10 |
| DAWN Day One Biopharmaceuticals I | New | 0.10% | +0.10 |
| ABEO Abeona Therapeutics Inc. | New | 0.10% | +0.10 |
| ALEC Alector Inc. | Add +272.0% | 0.18% | +0.09 |
| PYPD Polypid Ltd. | New | 0.09% | +0.09 |
| RNXT Renovorx Inc. | New | 0.08% | +0.08 |
Options Activity Q1 2024 → Q2 2024
| ALNY Alnylam Pharmaceuticals Inc. | put | Sold out | 234,400 | $35.0Mbefore exit |
| INSM Insmed Inc. | put | Add +11711.8% | 200,800 | $13.5M |
| INSM Insmed Inc. | call | New | 150,000 | $10.1M |
| SPY SS SPDR S&P 500 ETF Trust-US | put | Reduce -84.6% | 8,000 | $4.4M |
| GH Guardant Health Inc. | call | Sold out | 100,000 | $2.1Mbefore exit |
| ALNY Alnylam Pharmaceuticals Inc. | call | Sold out | 11,200 | $1.7Mbefore exit |
| QQQ Invesco QQQ Trust Series 1 | put | Reduce -70.0% | 3,000 | $1.4M |
| IWM iShares Russell 2000 ETF | put | New | 3,000 | $609K |
| MRNA Moderna Inc. | call | New | 5,000 | $594K |
| DJT Trump Media & Technology Gro | call | Sold out | 4,500 | $279Kbefore exit |
| APLT Applied Therapeutics Inc. | put | Sold out | 30,100 | $205Kbefore exit |
| SRPT Sarepta Therapeutics Inc. | call | Sold out | 1,200 | $155Kbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | New | 20,000 | $124K |
| BHVN Biohaven Ltd. | call | Sold out | 2,000 | $109Kbefore exit |
| CAPR Capricor Therapeutics Inc. | put | New | 20,400 | $97K |
| BBIO Bridgebio Pharma Inc. | call | New | 3,700 | $94K |
| AMLX Amylyx Pharmaceuticals Inc. | put | Sold out | 31,800 | $90Kbefore exit |
| RAPT THERAPEUTICS INC | put | Sold out | 7,500 | $67Kbefore exit |
| BHC Bausch Health Cos Inc. | call | Sold out | 6,000 | $64Kbefore exit |
| SVRA Savara Inc. | put | New | 11,000 | $44K |
| GLYCOMIMETICS INC | put | Reduce -3.0% | 135,000 | $38K |
| ANAB Anaptysbio Inc. | call | Reduce -25.0% | 1,500 | $38K |
| GPCR Structure Therapeutics Inc. | call | Sold out | 800 | $34Kbefore exit |
| SVRA Savara Inc. | call | New | 5,000 | $20K |
| AMLX Amylyx Pharmaceuticals Inc. | call | Reduce -86.5% | 10,000 | $19K |
| GOSS Gossamer Bio Inc. | call | New | 20,000 | $18K |
| AKBA Akebia Therapeutics Inc. | put | Sold out | 9,700 | $18Kbefore exit |
| EQ Equillium Inc. | call | Reduce -12.0% | 8,800 | $6K |
| CYTK Cytokinetics Inc. | call | Reduce -96.0% | 100 | $5K |
| AEROVATE THERAPEUTICS INC | call | New | 2,500 | $4K |
| APLS Apellis Pharmaceuticals Inc. | call | New | 100 | $4K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2024 → Q2 2024
| FLFVR Feutune Light Acquisitio-RTS | RIGHT 06/01/2029 | Sold out | 15,000 | $1Kbefore exit |
| FLFVW Feutune Light Acquisit -29 | *W EXP 06/01/202 | Sold out | 15,000 | $510before exit |
| FORLW Four Leaf Acquisition Cor-28 | *W EXP 03/15/202 | Reduce -15.8% | 7,987 | $360 |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |